Menu
Menu
Voting opens on March 1, 2023 and closes at 11:59 PM on April 30, 2023. The results will be announced in May, and the new terms will be effective as of July 1.
I am honored to be nominated for the Executive Committee of the Parkinson Study Group (PSG). Encouraged by my mentor, Robert Hamill, I applied and received membership to the PSG in 2008 and remain grateful for the numerous opportunities to contribute to the mission. My personal contributions to the PSG include serving as a site principal investigator on numerous multicenter trials, as an administrative investigator for provisional members, working group participation, faculty at the 2017 PSG CME event, and terms on the PSG Mentoring, Scientific Review, and Budget Review Committees. At my institution, I developed and serve as the director of a multidisciplinary comprehensive movement disorders center. I additionally serve as the director of our HDSA Level 2 Center of Excellence. My research has included serving as a site principal investigator in over 30 multicenter clinical trials in PD, HD, and other movement disorders. I have been a research mentor for students, residents, and PhD candidates through investigator-initiated projects.
As a member of the Executive Committee, I would vehemently work to ensure we continue to provide collaborative research and career development opportunities. Additionally, we will expand PSG research engagement to include the interfaces of technology, biomarkers, genetics, and novel therapeutics.
Dr. Andres Deik, MD, MSEd, FAAN completed his Neurology residency and Movement Disorders fellowship at Mount Sinai Beth Israel, and obtained a master’s in medical education at the University of Pennsylvania (Penn). He is now an Associate Professor of Clinical Neurology and Director of the Movement Disorders fellowship program at Penn.
A member since 2014, Dr. Deik is committed to the PSG and to the advancement of Parkinson’s (PD) therapeutics. He has served as site PI for multiple PSG-sponsored trials over the years, and, currently, leads an investigator-initiated trial at Penn’s Parkinson’s and Movement Disorders Center (PD&MDC). He was appointed director of experimental therapeutics at the center in 2014: in this role, Dr. Deik has overseen the execution of the clinical trial enterprise for almost a decade, with tasks including protocol review and selection, budget negotiation, resource allocation and recruitment, among others. PD&MDC currently runs over twenty research protocols in parallel, both NIH and industry-sponsored, and many of which focus on the evaluation of novel symptomatic and disease-modifying therapies for PD.
Finally, last year Dr. Deik was able to amalgamate his interests in medical education and research by volunteering in the PSG Symposium Committee for the 2022 Annual Meeting.
Dr. John Goudreau, DO, PhD is a physician-scientist jointly appointed in the Department of Neurology and Department of Pharmacology at Michigan State University and is the Director of the MSU Movement Disorders Clinic. He joined the faculty at MSU in 2001 after completing his neurology residency and movement disorders fellowship at Mayo Clinic. He also serves as the Associate Dean for Research in the MSU College of Osteopathic Medicine and as the Director of the Clinical Translational Science Institute in the MSU Office of the Vice President for Research and Innovation. His research is focused on basic, translational and clinical research for symptomatic and disease modifying therapies for Parkinson disease and movement disorders.
Dr. Goudreau became the founding director of the MSU Parkinson Study Group site in 2011. He has engaged in multiple PSG trials and served as the site primary investigator for the NINDS Exploratory Trials in PD. He has served the PSG Credentialing, Scientific Review, and Mentoring Committees and is involved with several PSG working groups. His involvement with the PSG has been a vital ingredient to his success and he welcomes any opportunity to further the PSG mission.
Gregory Pontone, M.D., M.H.S. is the director of the Parkinson’s disease Neuropsychiatry Clinic and an Associate Professor in the Departments of Psychiatry and Neurology at Johns Hopkins University School of Medicine in Baltimore, Maryland. After completing a medicine internship and residency training in psychiatry at Johns Hopkins, Dr. Pontone completed a two-year fellowship in geriatric psychiatry and movement disorders focusing on Parkinson’s disease through the Clinical Research Program of the Morris K. Udall Parkinson’s Disease Research Center. He also completed a fellowship in Clinical Trial Methods in Neurology sponsored by the National Institute of Neurological Disorders and Stroke. He is board certified by the American Board of Psychiatry and Neurology and has an added certification in the specialty of geriatric psychiatry. He is an editorial board member for the American Journal of Geriatric Psychiatry and Parkinsonism & Related Disorders. He has been a member of the Parkinson Study Group (PSG) since 2008. He currently serves on the Scientific Review Committee and as the chair of the Cognitive/Psychiatric Working Group. He has also served on the PSG Mentoring Committee and Professional Standards Committee.
Dr. Ruth Schneider is an Associate Professor of Neurology at the University of Rochester, where she also holds an appointment with the Center for Health & Technology and is the Director of the Huntington’s Disease Society of America Center of Excellence. After obtaining her undergraduate degree from Brown University in 2006, she completed medical school, neurology residency and movement disorders fellowship at the University of Rochester. Her research interests include the design of remote clinical research studies, development of digital disease measures, and study of neuropsychiatric features of Parkinson’s disease. She has led several externally-funded, investigator-initiated studies, has served as a medical monitor, and has served as a site investigator for several multi-center studies. She is the co-PI for one of the University of Rochester’s Morris K. Udall Center of Excellence for Parkinson’s Disease Research core studies – VALOR-PD – which is a remote, observational study of ~275 LRRK2 carriers. Since joining the PSG in 2015, she has been actively involved as an investigator, working group member, speaker, and Mentorship Committee member. Dr. Schneider also leads the team responsible for conducting study visits for AT-HOME PD, a remote, observational PSG study of ~225 former STEADY-PD III and SURE-PD3 participants.
I have been a PSG member since 2007. I am an Associate Professor of Neurology at Harvard Medical School, Chief of the Division of Sleep Medicine at Massachusetts General Hospital (MGH), and Director of the Program on Sleep, Circadian Biology, and Neurodegeneration. As a clinician-scientist trained in Movement Disorders and Sleep Medicine, I have devoted my research to (i) clinical trials in neurodegenerative disorders and (ii) the interface of sleep, circadian biology, and neurodegeneration. I have expertise and experience in clinical research, including study design and implementation, which spans all phases of clinical development and includes common and rare neurological disorders. I am a Co-PI of the Clinical Coordination Center at MGH for the NINDS NeuroNEXT clinical trials network. I am MGH PI for the PPMI and serve on its Executive Steering Committee. I am MGH PI for the North American Prodromal Synucleinopathy (NAPS) RBD Consortium, where I also serve as a Co-Lead of the Recruitment, Education, and Outreach Core. I served as Chair of the PSG Other Non-Motor Features Workgroup. It would be a privilege to serve on the PSG Executive Committee. I thank the PSG for the honor of this nomination.
You must be logged in to vote and have a completed PSG profile.
